ZYDUS LIFESCIENCES LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,097 INR | +4.38% |
|
+11.77% | +59.52% |
| 09:05am | Nomura Downgrades Zydus Lifesciences to Neutral From Buy, Adjusts Price Target to INR1,020 From INR988 | MT |
| 08:46am | Zydus Lifesciences Records Sharp Rise in Fiscal Q4 Consolidated Profit | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
| Sales 2024 | 20TCr 234.63Cr | Sales 2025 * | 22TCr 259.81Cr | Capitalization | 1,11100Cr 1.33TCr |
|---|---|---|---|---|---|
| Net income 2024 | 3.86TCr 46Cr | Net income 2025 * | 4.45TCr 53Cr | EV / Sales 2024 | 5.19 x |
| Net cash position 2024 * | 1.35TCr 16Cr | Net cash position 2025 * | 2.93TCr 35Cr | EV / Sales 2025 * | 5 x |
| P/E ratio 2024 |
26.4
x | P/E ratio 2025 * |
26.3
x | Employees | 23,026 |
| Yield 2024 * |
0.52% | Yield 2025 * |
0.5% | Free-Float | 24.87% |
More Fundamentals
* Assessed data
More news
Latest transcript on Zydus Lifesciences Limited
More recommendations
More press releases
| 1 day | +4.57% | ||
| 1 week | +11.77% | ||
| Current month | +15.30% | ||
| 1 month | +14.56% | ||
| 3 months | +23.00% | ||
| 6 months | +72.04% | ||
| Current year | +59.52% |
1 week
983.65
1 172.50
1 month
914.501 172.50
Current year
686.001 172.50
1 year
484.951 172.50
3 years
319.001 172.50
5 years
202.001 172.50
10 years
178.451 172.50
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 44 | 01/97/01 | |
| Director of Finance/CFO | - | - | |
| Chairman | 71 | 15/95/15 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 72 | 06/18/06 | |
| Chairman | 71 | 15/95/15 | |
| Director/Board Member | 69 | 01/97/01 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.22% | 6 M€ | +6.07% | - | |
| 0.01% | 112 M€ | +5.31% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 21/24/21 | 1,097 | +4.38% | 3 941 198 |
| 18/24/18 | 1,104 | +5.00% | 71,808 |
| 17/24/17 | 1,051 | +4.20% | 3,018,435 |
| 16/24/16 | 1,009 | +1.20% | 1,608,100 |
| 15/24/15 | 997 | +1.36% | 1,174,315 |
Delayed Quote NSE India S.E., May 21, 2024 at 02:39 pm IST
More quotes
Zydus Lifesciences Limited is an India-based global life sciences company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The Company is engaged in the business of integrated pharmaceutical operations. Its product portfolio includes active pharmaceutical ingredients (API), human formulations, animal health and veterinary, health, and wellness products. Its products include India formulations, Generics and Zydus biologics. The Company's products include Lipaglyn and Bilypsa (Saroglitazar), Ujvira (Trastuzumab emtansine biosimilar), Exemptia (Adalimumab biosimilar), Vivitra (Trastuzumab biosimilar) and Bryxta (Bevacizumab biosimilar). Its Zydus biologics covers various therapeutic areas, such as oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology and infectious illnesses, among others. The Company has a global presence and markets its products in the United States, India, Europe and emerging markets.
Sector
Pharmaceuticals
Calendar
07/08/2024
- Q1 2025 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
1,104
INR
Average target price
925.2
INR
Spread / Average Target
-16.19%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +59.52% | 1.33TCr | |
| +22.95% | 4.41TCr | |
| +22.22% | 2.26TCr | |
| +17.81% | 1.51TCr | |
| +15.83% | 1.36TCr | |
| -8.98% | 693.96Cr | |
| -0.05% | 678.76Cr | |
| -8.87% | 572.55Cr | |
| +15.65% | 575.2Cr | |
| +6.11% | 477.97Cr |
- Stock Market
- Equities
- ZYDUSLIFE Stock
